Sugi Predict

Sugi Predict / Compounds / SCHEMBL670584

SCHEMBL670584

SCHEMBL670584

COC(=O)c1cc([N+](=O)[O-])c(N)c(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 1/20 0.47
▸ FGFR1 P11362 1/20 0.47
▸ PDGFRA P16234 1/20 0.47
▸ FLT1 P17948 1/20 0.47
▸ FGFR3 P22607 1/20 0.47
▸ KDR P35968 1/20 0.47
▸ VCAM1 P19320 1/20 0.43
▸ ALDH1A1 P00352 6/20 0.42
▸ LMNA P02545 3/20 0.42
▸ SIRT6 Q8N6T7 1/20 0.41
▸ GAA P10253 2/20 0.41
▸ KDM4E B2RXH2 5/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ G6PD P11413 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7539373 0.98 PDGFRB (0.46) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2522874 0.91 PDGFRB (0.47) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL18752885 0.88 PDGFRB (0.48) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL1076321 0.87 PDGFRB (0.44) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2522809 0.86 PDGFRB (0.50) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL5740305 0.85 MEN1 (0.41) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL11992726 0.84 PDGFRB (0.44) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL5212870 0.83 PDGFRB (0.48) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL505648 0.82 ALDH1A1 (0.45) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL8079569 0.82 PDGFRB (0.50) PDGFRBFGFR1PDGFRAFLT1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340518-A1 PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF GLENMARK LIFE SCIENCES LTD (IN) 2025-11-06 — — US disclosed
EP-4536226-A1 PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF Alivus Life Sciences Limited (IN) 2025-04-16 — — EP disclosed
CN-115490640-B Substituted benzimidazoles, compositions containing them and their use 深圳市塔吉瑞生物医药有限公司 2024-11-26 — — CN disclosed
WO-2024003942-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF SELUMETINIB SULFATE NATCO PHARMA LIMITED (IN) 2024-01-04 — — WO disclosed
WO-2023238000-A1 PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF GLENMARK LIFE SCIENCES LIMITED (IN) 2023-12-14 — — WO disclosed
US-20230192625-A1 SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME SHENZHEN TARGETRX, INC. (CN) 2023-06-22 — — US disclosed
CN-115490640-A Substituted benzimidazoles, compositions containing them and their use 深圳市塔吉瑞生物医药有限公司 2022-12-20 — — CN disclosed
WO-2020212832-A1 PROCESS OF PREPARATION OF BENZIMIDAZOLE COMPOUNDS ALEMBIC PHARMACEUTICALS LIMITED (IN) 2020-10-22 — — WO disclosed
EP-1904061-B1 SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS ARRAY BIOPHARMA INC (US) 2018-12-26 — — EP disclosed
EP-2827901-B1 COMBINATION THERAPY OF A MEK INHIBITOR AND AN IGF1R INHIBITOR NOVARTIS AG (CH) 2017-09-06 — — EP disclosed
US-20040116710-A1 N3 alkylated benzimidazole derivatives as MEK inhibitors ASTRAZENECA AB (SE) 2004-06-17 — — US disclosed
US-20030232869-A1 N3 alkylated benzimidazole derivatives as MEK inhibitors ASTRAZENECA AB (SE) 2003-12-18 — — US disclosed
US-20030216460-A1 N3 alkylated benzimidazole derivatives as MEK inhibitors ARRAY BIOPHARMA, INC. 2003-11-20 — — US disclosed
WO-2003077855-A2 N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS ARRAY BIOPHARMA, INC (US) 2003-09-25 — — WO disclosed
WO-2003077914-A1 N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS ARRAY BIOPHARMA, INC (US) 2003-09-25 — — WO disclosed
US-6469004-B1 Benzoheterocycles and their uses as MEK inhibitors WARNER-LAMBERT COMPANY 2002-10-22 — — US disclosed
EP-1202731-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-05-08 — — EP disclosed
EP-1144385-A1 BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-10-17 — — EP disclosed
WO-2001005390-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-01-25 — — WO disclosed
WO-2000042022-A1 BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-07-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340518-A1 PROCESS FOR PREPARATION OF SELUMETINIB AND SALTS THEREOF BRAF, KRAS, JAK2 PDGFRB 284/4885FGFR1 147/4885PDGFRA 272/4885
US-20230192625-A1 SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION COMPRISING SAME REN, BRAF, CDK4 PDGFRB 109/4885FGFR1 66/4885PDGFRA 132/4885
US-20030232869-A1 N3 alkylated benzimidazole derivatives as MEK inhibitors CCNI, BRAF, CDK2 PDGFRB 536/4885FGFR1 572/4885PDGFRA 562/4885
US-20030216460-A1 N3 alkylated benzimidazole derivatives as MEK inhibitors CCNI, BRAF, CCNT1 PDGFRB 482/4885FGFR1 668/4885PDGFRA 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.